SKF-97541

A highly potent agonist of GABA_B receptor. Depresses excitatory postsynaptic potentials mediated by glutamate in the striatum, and hyperpolarized neurones in the substantia nigra (IC₅₀ = 92 nM). Shown to be about 10-times more potent than baclofen (Cat. No. 505873). Induces vasodepression in pulmonary vascular bed that is modulated by an ATP-sensitive K+ channel. Induces gastric acid secretion in a dose-dependent manner (0.01 - 3 mg/kg, i.v.) in mice.

A highly potent agonist of GABA_B receptor. Depresses excitatory postsynaptic potentials mediated by glutamate in the striatum, and hyperpolarized neurones in the substantia nigra (IC₅₀ = 92 nM). Shown to be about 10-times more potent than baclofen (Cat. No. 505873). Induces vasodepression in pulmonary vascular bed that is modulated by an ATP-sensitive K+ channel. Induces gastric acid secretion in a dose-dependent manner (0.01 - 3 mg/kg, i.v.) in mice.

Please note that the molecular weight for this compound is batch-specific due to variable water content.

Primary Target
GABA_B

Packaged under inert gas

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Kaye, A.D., et al. 2004. Anesth. Analg.99, 758.
Piqueras, L., and Martinez, V. 2004. Br. J. Pharmacol.142, 1038.

Seabrook, G.R., et al. 1990. Br. J. Pharmacol.101, 949.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany